My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Allocation Agreement with exhibits - final
>
Meetings
>
2022
>
09. September
>
2022-09-06 10:00 AM - Commissioners' Agenda
>
Allocation Agreement with exhibits - final
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/1/2022 1:11:41 PM
Creation date
9/1/2022 1:10:08 PM
Metadata
Fields
Template:
Meeting
Date
9/6/2022
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Authorizing the Chair's Signature on a Opioid Litigation Allocation Agreement
Order
3
Placement
Consent Agenda
Row ID
93293
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
106
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
FINAL AGREEMENT 3.25.22 <br />4. Research on novel harm reduction and prevention efforts such as the <br />provision of fentanyl test strips. <br />5. Research on innovative supply-side enforcement efforts such as improved <br />detection of mail -based delivery of synthetic opioids. <br />6. Expanded research on swift/certain/fair models to reduce and deter opioid <br />misuse within criminal justice populations that build upon promising <br />approaches used to address other substances (e.g., Hawaii HOPE and <br />Dakota 24/7). <br />7. Epidemiological surveillance of OUD-related behaviors in critical <br />populations, including individuals entering the criminal justice system, <br />including, but not limited to approaches modeled on the Arrestee Drug <br />Abuse Monitoring ("ADAM") system. <br />8. Qualitative and quantitative research regarding public health risks and <br />harm reduction opportunities within illicit drug markets, including surveys <br />of market participants who sell or distribute illicit opioids. <br />9. Geospatial analysis of access barriers to MAT and their association with <br />treatment engagement and treatment outcomes. <br />E-15 <br />
The URL can be used to link to this page
Your browser does not support the video tag.